Positive News SentimentPositive NewsNASDAQ:ACIU AC Immune (ACIU) Stock Price, News & Analysis $2.99 -0.12 (-3.86%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.98▼$3.1250-Day Range$2.99▼$4.2052-Week Range$2.20▼$5.14Volume101,812 shsAverage Volume413,125 shsMarket Capitalization$295.71 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AC Immune alerts: Email Address AC Immune MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside301.3% Upside$12.00 Price TargetShort InterestHealthy1.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.54) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.97 out of 5 starsMedical Sector338th out of 910 stocksPharmaceutical Preparations Industry145th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingAC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAC Immune has received no research coverage in the past 90 days.Read more about AC Immune's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.27% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AC Immune has recently decreased by 16.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACIU. Previous Next 3.3 News and Social Media Coverage News SentimentAC Immune has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows3 people have added AC Immune to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of AC Immune is held by insiders.Percentage Held by Institutions51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AC Immune's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.54) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AC Immune's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About AC Immune Stock (NASDAQ:ACIU)AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Read More ACIU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACIU Stock News HeadlinesAugust 31, 2024 | americanbankingnews.comAC Immune SA (NASDAQ:ACIU) Short Interest Down 16.4% in AugustAugust 29, 2024 | marketwatch.comAC Immune Gets FDA Fast-Track Designation for Neurodegenerative Diagnostic ScanSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 29, 2024 | markets.businessinsider.comAC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative ConditionsAugust 28, 2024 | americanbankingnews.comAC Immune (NASDAQ:ACIU) and Minerva Neurosciences (NASDAQ:NERV) Head-To-Head SurveyAugust 23, 2024 | finance.yahoo.comThe past three years for AC Immune (NASDAQ:ACIU) investors has not been profitableAugust 15, 2024 | msn.comCan Your AC Really Make You Sick? Experts Reveal the TruthAugust 7, 2024 | markets.businessinsider.comBuy Rating on AC Immune SA for Promising Alzheimer’s and Parkinson’s VaccinesSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 6, 2024 | finance.yahoo.comAC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateJuly 31, 2024 | globenewswire.comAC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024July 25, 2024 | finanznachrichten.deAC Immune SA: AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's DiseaseJuly 25, 2024 | markets.businessinsider.comAC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s DiseaseJuly 25, 2024 | globenewswire.comAC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's DiseaseMay 28, 2024 | globenewswire.comAC Immune to Present at the Jefferies Global Healthcare Conference in June 2024May 21, 2024 | finance.yahoo.comIndividual investors own 24% of AC Immune SA (NASDAQ:ACIU) shares but private equity firms control 30% of the companyMay 16, 2024 | markets.businessinsider.comBuy Rating Justified by Strategic Partnerships and Promising Pipeline in AC Immune SAMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed: AC Immune’s Promising Alzheimer’s Vaccine and Strategic Takeda PartnershipSee More Headlines Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACIU CUSIPN/A CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$16.00 Low Stock Price Target$8.00 Potential Upside/Downside+301.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,410,000.00 Net MarginsN/A Pretax Margin-391.24% Return on Equity-43.72% Return on Assets-33.24% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual Sales$15.49 million Price / Sales19.09 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book2.17Miscellaneous Outstanding Shares98,899,000Free Float94,350,000Market Cap$295.71 million OptionableOptionable Beta1.27 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Andrea Pfeifer Ph.D. (Age 67)Co-Founder, CEO & Director Comp: $1.09MMr. Christopher Roberts (Age 34)CFO & VP of Finance Mr. Piergiorgio Donati (Age 53)Chief Technical Operations Officer Mr. Jean-Fabien Monin (Age 53)Chief Administrative Officer Mr. Howard Donovan (Age 48)Chief HR Officer Ms. Madiha Derouazi (Age 51)Chief Scientific Officer Dr. Gary Anthony Waanders Ph.D. (Age 60)Senior VP of Investor Relations & Corporate Communications Mr. Alexandre Caratsch (Age 58)General Counsel Mr. Julian SnowVP of U.S. Finance & Corporate DevelopmentDr. David T. HickmanHead of AD - SMEMore ExecutivesKey CompetitorsTarsus PharmaceuticalsNASDAQ:TARSGyre TherapeuticsNASDAQ:GYRENurix TherapeuticsNASDAQ:NRIXCogent BiosciencesNASDAQ:COGTSpyre TherapeuticsNASDAQ:SYREView All CompetitorsInstitutional OwnershipCubist Systematic Strategies LLCBought 54,610 shares on 8/14/2024Ownership: 0.055%Renaissance Technologies LLCBought 136,300 shares on 8/9/2024Ownership: 0.659%Vanguard Capital Wealth AdvisorsBought 14,000 shares on 8/8/2024Ownership: 0.014%Banque Cantonale VaudoiseSold 28,716 shares on 7/31/2024Ownership: 0.026%Assenagon Asset Management S.A.Bought 328,312 shares on 7/18/2024Ownership: 0.445%View All Institutional Transactions ACIU Stock Analysis - Frequently Asked Questions How have ACIU shares performed this year? AC Immune's stock was trading at $5.00 at the beginning of 2024. Since then, ACIU stock has decreased by 40.2% and is now trading at $2.99. View the best growth stocks for 2024 here. How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) released its earnings results on Tuesday, August, 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by $0.67. The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $91.60 million. What is Andrea Pfeifer's approval rating as AC Immune's CEO? 3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did AC Immune IPO? AC Immune (ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. Who are AC Immune's major shareholders? Top institutional investors of AC Immune include Renaissance Technologies LLC (0.66%), Assenagon Asset Management S.A. (0.44%), Cubist Systematic Strategies LLC (0.06%) and Banque Cantonale Vaudoise (0.03%). How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO) and Catalyst Pharmaceuticals (CPRX). This page (NASDAQ:ACIU) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACIU Stock Alerts